- $11.25m
- $9.50m
- $0.57m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.81 | ||
| Price to Tang. Book | 6.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 77.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -863.32% | ||
| Return on Equity | -1004.77% | ||
| Operating Margin | -18526.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.52 | 0.63 | 0.9 | 0.28 | 0.57 | n/a | n/a | -4.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- April 6th, 2001
- Public Since
- August 9th, 2018
- No. of Shareholders
- 144
- No. of Employees
- 37
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 1,584,300
- Address
- 1895 Mount Hope Ave, ROCHESTER, 14620-4540
- Web
- https://www.vaccinex.com/
- Phone
- +1 5852712700
- Contact
- Michael Rice
- Auditors
- Deloitte & Touche LLP
Upcoming Events for VCNX
Q3 2024 Vaccinex Inc Earnings Release
Similar to VCNX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Vaccinex share price?
As of Today at 23:57 UTC, shares in Vaccinex are trading at $6.10. This share price information is delayed by 15 minutes.
How has the Vaccinex share price performed this year?
Shares in Vaccinex last closed at $6.10 and the price had moved by -92.17% over the past 365 days. In terms of relative price strength the Vaccinex share price has underperformed the S&P500 Index by -93.77% over the past year.
What are the analyst and broker recommendations for Vaccinex?
The overall consensus recommendation for Vaccinex is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Vaccinex dividend yield?
Vaccinex does not currently pay a dividend.
Does Vaccinex pay a dividend?
Vaccinex does not currently pay a dividend.
When does Vaccinex next pay dividends?
Vaccinex does not currently pay a dividend.
How do I buy Vaccinex shares?
To buy shares in Vaccinex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vaccinex?
As of the previous close price of $6.10, shares in Vaccinex had a market capitalisation of $9.66m.
Where are Vaccinex shares listed?
Here are the trading details for Vaccinex:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VCNX
What kind of share is Vaccinex?
Based on an overall assessment of its quality, value and momentum Vaccinex is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vaccinex share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Vaccinex share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaccinex. Over the past six months, its share price has underperformed the S&P500 Index by -45.78%.
As of the last closing price of $6.10, shares in Vaccinex were trading -45.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vaccinex PE Ratio?
The Vaccinex PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vaccinex?
We do not have data on Vaccinex's directors